Home › Compare › ARTLW vs DIVO

ARTLW vs DIVO: Dividend Comparison 2026

ARTLW yields 35714.29% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARTLW wins by $1.6752839315172392e+22M in total portfolio value
10 years
ARTLW
ARTLW
● Live price
35714.29%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6752839315172392e+22M
Annual income
$16,661,069,746,468,538,000,000,000,000.00
Full ARTLW calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — ARTLW vs DIVO

📍 ARTLW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARTLWDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARTLW + DIVO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ARTLW pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARTLW
Annual income on $10K today (after 15% tax)
$3,035,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,161,909,284,498,257,000,000,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, ARTLW beats the other by $14,161,909,284,498,257,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARTLW + DIVO for your $10,000?

ARTLW: 50%DIVO: 50%
100% DIVO50/50100% ARTLW
Portfolio after 10yr
$8.376419657586196e+21M
Annual income
$8,330,534,873,234,269,000,000,000,000.00/yr
Blended yield
99.45%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARTLW buys
0
DIVO buys
0
No recent congressional trades found for ARTLW or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARTLWDIVO
Forward yield35714.29% ✓6.49%
Annual dividend / share$2.00$2.91 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.6752839315172392e+22M$30.7K ✓
Annual income after 10y$16,661,069,746,468,538,000,000,000,000.00 ✓$981.68
Total dividends collected$1.6746806834400388e+22M$8.2K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ARTLW vs DIVO ($10,000, DRIP)

YearARTLW PortfolioARTLW Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$3,582,129$3,571,428.57$11,349$649.42+$3.57M → ARTLW
2$1,199,469,917$1,195,637,039.86$12,833$688.83+$1199.46M → ARTLW
3$375,448,961,128$374,165,528,316.29$14,459$727.90+$375448.95M → ARTLW
4$109,858,226,763,271$109,456,496,374,863.77$16,238$766.49+$109858226.75M → ARTLW
5$30,049,803,731,826,150$29,932,255,429,189,452.00$18,179$804.47+$30049803731.81M → ARTLW
6$7,683,972,846,060,485,000$7,651,819,556,067,430,000.00$20,293$841.71+$7683972846060.46M → ARTLW
7$1,836,848,834,513,013,000,000$1,828,626,983,567,728,800,000.00$22,591$878.14+$1836848834513013.00M → ARTLW
8$410,500,120,243,639,900,000,000$408,534,691,990,711,000,000,000.00$25,087$913.65+$410500120243639936.00M → ARTLW
9$85,765,952,059,675,500,000,000,000$85,326,716,931,014,800,000,000,000.00$27,791$948.18+$85765952059675492352.00M → ARTLW
10$16,752,839,315,172,392,000,000,000,000$16,661,069,746,468,538,000,000,000,000.00$30,718$981.68+$1.6752839315172392e+22M → ARTLW

ARTLW vs DIVO: Complete Analysis 2026

ARTLW — Stock

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Full ARTLW Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this ARTLW vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARTLW vs SCHDARTLW vs JEPIARTLW vs OARTLW vs KOARTLW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.